TAIPEI/TOKYO -- A Taiwanese biopharmaceutical startup aspires to become a global player via the same tactics that compatriot Taiwan Semiconductor Manufacturing Co. employed to find success in the chip sector, extending Taiwan's so-called silicon shield into new domains.
Pharmaceuticals
Taiwan biopharmaceutical startup takes page from TSMC's playbook
TBMC emulates chipmaker in more than name, aiming to shield home island from risk
.JPG?width=780&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto)
Taiwan Bio-Manufacturing Corp. aims to begin mass production in 2027. (TBMC)
Read Next
Latest on Pharmaceuticals
